Evotec (NASDAQ:EVO) Releases Earnings Results, Misses Expectations By $0.25 EPS

Key Points

• Evotec reported an EPS loss of ($0.40), missing consensus by $0.25, and revenue of $181.32M versus estimates of $239.17M, leaving the company with a negative net margin and return on equity.
• The firm has moved its "Horizon" transformation into implementation, booking EUR 75m of restructuring provisions and targeting ~EUR 75m of structural run‑rate savings by end‑2027 (20–30% expected in 2026), while reiterating 2026 guidance of EUR 700–780m revenue and EUR 0–40m adj. EBITDA and appointing new CFO/COO/CCO to lead the turnaround.
• Liquidity remains strong with a net cash position of EUR 444.8m, and management expects ~USD 100m of gross proceeds in Q2 from Gilead’s acquisition of Tubulis to further bolster cash resources.

Evotec (NASDAQ:EVO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.25), FiscalAI reports. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%.The firm had revenue of $181.32 million for the quarter, compared to analyst estimates of $239.17 million.

Here are the key takeaways from Evotec's conference call:

• Evotec has moved Horizon from announcement into implementation, recording EUR 75m of restructuring provisions in Q1 and targeting ~EUR 75m of structural run‑rate savings by end‑2027 (20–30% expected to materialize in 2026).
• Q1 revenue was EUR 156.6m and adjusted EBITDA was negative EUR 21.9m, with management citing a non‑recurring $25m Sandoz license, FX headwinds and D&PD softness; the company reiterated full‑year 2026 guidance (EUR 700–780m revenue; EUR 0–40m adj. EBITDA).
• Leadership was strengthened with appointments of Claire Hinshelwood as CFO, Ingrid Muller as COO and Ashiq H. Khan as CCO to drive financial continuity, operational delivery and commercial execution during the transformation.
• Early commercial indicators improved: proposal activity reached a 12‑month high, negative change orders declined, proposal turnaround times shortened and net sales orders were up ~15% year‑on‑year, supporting management's expectation of H2 recovery.
• Liquidity remains solid at EUR 444.8m (net cash position) and management expects ~USD 100m of gross proceeds in Q2 from the Gilead acquisition of Tubulis, which will further bolster cash resources.

Evotec Trading Up 1.3%

Shares of EVO stock traded up $0.04 on Wednesday, reaching $3.24. The stock had a trading volume of 139,333 shares, compared to its average volume of 109,128. Evotec has a 1 year low of $2.31 and a 1 year high of $4.80. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.99 and a current ratio of 2.07. The company has a 50 day simple moving average of $2.85 and a 200 day simple moving average of $3.22.

Hedge Funds Weigh In On Evotec

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd boosted its stake in shares of Evotec by 25.1% in the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock worth $57,000 after buying an additional 3,709 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Evotec by 25.7% in the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company's stock worth $5,536,000 after buying an additional 367,545 shares during the last quarter. OLD Mission Capital LLC purchased a new position in shares of Evotec in the 4th quarter worth $158,000. Millennium Management LLC purchased a new position in Evotec during the fourth quarter valued at $317,000. Finally, Marshall Wace LLP purchased a new position in Evotec during the fourth quarter valued at $40,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EVO. Wall Street Zen upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Saturday, January 10th. Weiss Ratings upgraded Evotec from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Berenberg Bank began coverage on Evotec in a research note on Tuesday, February 3rd. They set a "buy" rating on the stock. Finally, HC Wainwright began coverage on Evotec in a research note on Wednesday, April 15th. They set a "buy" rating and a $7.00 target price on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $7.00.

About Evotec

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.